Related Experiment Video

Updated: Apr 17, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.9K

Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer

Benjamin Solomon1

  • 1Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia ben.solomon@petermac.org.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|February 11, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

549

Related Experiment Videos

Last Updated: Apr 17, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

549

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

Articles linked to this work by shared authors, journal, and citation graph.

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

Lung cancer (Amsterdam, Netherlands)·2026

Diagnostic Delays in Thoracic Cancer Care: A Data-Linkage, Cohort Study between Primary Care, Hospital, and Registry Data.

Health data science·2026

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Clinical and translational radiation oncology·2026

Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us